Zimmer Floats Divestments To Win European Approval Of Biomet Acquisition
This article was originally published in The Gray Sheet
Zimmer is negotiating with the European Commission on a strategic divestment strategy that would allow European anti-trust regulators to approve Zimmer’s pending acquisition of Biomet.
You may also be interested in...
Zimmer and Biomet will drop some knee and elbow product lines to satisfy European regulator concerns over its planned $13.35 billion merger.
Zimmer has agreed to buy Biomet by the first quarter of 2015, furthering the trend of consolidation in the $45 billion orthopedic device industry. The companies had combined revenues of $7.8 billion in 2013.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.